دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Platelet Reactivity in Patients With Acute Coronary Syndromes Awaiting Surgical Revascularization
Carlos A.K.NakashimaMDaLuis A.O.DallanMD, PhDaLuiz A.F.LisboaMDaFabio B.JateneMD, PhDaLudhmila A.HajjarMD, PhDaAlexandre M.SoeiroMDaRemo H.M.FurtadoMDabTalia F.DalçoquioMDaLuciano M.BaracioliMDaFelipe G.LimaMDaRoberto R.C.V.GiraldezMD, PhDaBianca A.SilvaMDaMateus S.S.CostaMDaCelia M.C.StrunzPhDaLuis R.P.DallanMDaCarlos J.D.G.BarbosaMDcFlavia A.B.BrittoMDdeMichael E.FarkouhMD, MScdePaul A.GurbelMD, PhDfJose C.NicolauMD, PhDa
doi : 10.1016/j.jacc.2021.01.015
Volume 77, Issue 10, 16 March 2021, Pages 1277-1286
Dual antiplatelet therapy is recommended for patients with acute coronary syndromes (ACS). Approximately 10% to 15% of these patients will undergo coronary artery bypass graft (CABG) surgery for index events, and current guidelines recommend stopping clopidogrel at least 5 days before CABG. This waiting time has clinical and economic implications.
Does Platelet Reactivity Testing Predict Post-Operative Bleeding Risk??
John A.BittlMD
doi : 10.1016/j.jacc.2021.01.016
Volume 77, Issue 10, 16 March 2021, Pages 1287-1289
Systolic Blood Pressure Time in Target Range and Cardiovascular Outcomes in Patients With Hypertension
NayyraFataniPharmDabcDave L.DixonPharmDdBenjamin W.Van TassellPharmDdJohnFanikosRPh, MBAcLeo F.BuckleyPharmDc
doi : 10.1016/j.jacc.2021.01.014
Volume 77, Issue 10, 16 March 2021, Pages 1290-1299
Standard blood pressure control metrics may not account for fluctuations in blood pressure over time.
Time in Therapeutic Range: Redefining “Optimal” Blood Pressure Control?
GeorgeBakrisMDaHillelSternlichtMDb
doi : 10.1016/j.jacc.2021.01.019
Volume 77, Issue 10, 16 March 2021, Pages 1300-1301
Hypertensive Disorders of Pregnancy and Subsequent Risk of Premature Mortality
Yi-XinWangMD, PhDaMarielArvizuMD, ScDaJanet W.Rich-EdwardsScDbcLiangWangDrPHadBernardRosnerPhDefJennifer J.StuartScDbcKathryn M.RexrodeMDcJorge E.ChavarroMD, ScDabf
doi : 10.1016/j.jacc.2021.01.018
Volume 77, Issue 10, 16 March 2021, Pages 1302-1312
Hypertensive disorders of pregnancy (HDPs) are leading causes of maternal and perinatal morbidity and mortality. However, it is uncertain whether HDPs are associated with long-term risk of premature mortality (before age 70 years).
Can We Reduce Premature Mortality Associated With Hypertensive Disorders of Pregnancy?: A Window of Opportunity?
GarimaSharmaMDAllison G.HaysMDRoger S.BlumenthalMD
doi : 10.1016/j.jacc.2021.01.021
Volume 77, Issue 10, 16 March 2021, Pages 1313-1316
Impact of Obesity on Outcomes of Pregnancy in Women With Heart Disease
BirgitPfallerMDabSamuel C.SiuMD, SM, MBAacRohanD'SouzaMD, PhDdBarbaraWichert-SchmittMDaeGovind KrishnaKumar NairBScaKimHabererMDaCynthiaMaxwellMDdCandice K.SilversidesSM, MDa
doi : 10.1016/j.jacc.2021.01.010
Volume 77, Issue 10, 16 March 2021, Pages 1317-1326
Women with heart disease are at risk for complications during pregnancy. This study sought to examine the effect of maternal obesity on pregnancy complications in women with heart disease.
Is Maternal Obesity the Achilles’ Heel of Sustainable Efforts to Reduce Adverse Pregnancy Outcomes??
GarimaSharmaMDaRoger S.BlumenthalMDaAthenaPoppasMDb
doi : 10.1016/j.jacc.2021.01.023
Volume 77, Issue 10, 16 March 2021, Pages 1327-1330
Heart-After-Liver Transplantation Attenuates Rejection of Cardiac Allografts in Sensitized Patients
Richard C.DalyMDaAndrew N.RosenbaumMDbcJoseph A.DearaniMDaAlfredo L.ClavellMDbcNaveen L.PereiraMDbcBarry A.BoilsonMDbcRobert P.FrantzMDbcAttaBehfarMD, PhDbcdShannon M.DunlayMDbceRichard J.RodehefferMDbcJohn A.SchirgerMDbcTimucinTanerMD, PhDfgManish J.GandhiMDhJulie K.HeimbachMDfCharles B.RosenMDfBrooks S.EdwardsMDbcSudhir S.KushwahaMDbc
doi : 10.1016/j.jacc.2021.01.013
Volume 77, Issue 10, 16 March 2021, Pages 1331-1340
In patients undergoing heart transplantation, significant allosensitization limits access to organs, resulting in longer wait times and high waitlist mortality. Current desensitization strategies are limited in enabling successful transplantation.
Toward Immunomodulation in Heart Transplantation: 2 Organs Are Better Than 1?
G. WilliamDecMDaJagatNarulaMD, PhDb
doi : 10.1016/j.jacc.2021.01.039
Volume 77, Issue 10, 16 March 2021, Pages 1341-1343
Ambulatory Electrocardiogram Monitoring in Patients Undergoing Transcatheter Aortic Valve Replacement: JACC State-of-the-Art Review
GuillemMuntané-CarolMDaFrançoisPhilipponMDaIsabelleNaultMDaLaurentFarouxMDaAlbertoAlperiMDaSuneetMittalMDbJosepRodés-CabauMD, PhDac
doi : 10.1016/j.jacc.2020.12.062
Volume 77, Issue 10, 16 March 2021, Pages 1344-1356
Transcatheter aortic valve replacement (TAVR) has changed the treatment of patients with severe aortic stenosis. However, the occurrence of conduction disturbances has not decreased significantly over time and remains the main drawback of the procedure. In addition, new-onset atrial fibrillation is the most frequent tachyarrhythmia during the hospitalization period and is associated with worse clinical outcomes. However, little is known regarding the incidence and clinical impact of arrhythmic events beyond the periprocedural TAVR period. Ambulatory electrocardiogram (AECG) monitoring has recently emerged as a tool to unravel the complex issue of arrhythmic disorders (bradyarrhythmias and tachyarrhythmias) before and after TAVR. To date, the preliminary results from the initial experience using AECG monitoring systems showed the safety, usefulness, and potential clinical implications of this diagnostic tool in TAVR recipients. This review provides an overview of the current status, clinical implications, and future perspectives of AECG monitoring in the TAVR setting.
A Test in Context: Interpretation of High-Sensitivity Cardiac Troponin Assays in Different Clinical Settings
InbarRaberMDaCian P.McCarthyMB, BCh, BAObJames L.JanuzziJr.MDbc
doi : 10.1016/j.jacc.2021.01.011
Volume 77, Issue 10, 16 March 2021, Pages 1357-1367
High-sensitivity cardiac troponin (hs-cTn) assays have the ability to detect minute troponin concentrations and resolve minor changes in biomarker concentrations. Clinically, this allows for the ability to rapidly identify or exclude acute myocardial injury in the setting of acute chest discomfort—thus providing more rapid evaluation for acute myocardial infarction—but the improvements in troponin assays also create avenues for other applications where troponin release from the cardiomyocyte might confer prognostic information. These situations include cardiovascular risk assessment across a wide range of clinical circumstances, including apparently-well individuals, those at risk for heart disease, and those with prevalent cardiovascular disorders. The optimal hs-cTn threshold for each circumstance varies by the assay used and by the population assessed. This review will provide context for how hs-cTn assays might be interpreted depending on the application sought, reviewing results from studies leveraging hs-cTn for applications beyond “acute myocardial infarction diagnostic evaluation.”
COVID-19 and the Athlete: Gaining Ground But Not Yet at the Finish
AthenaPoppasMD, FACC(President, American College of Cardiology)Eugene H.ChungMD, FACC(ACC Sports and Exercise Cardiology Leadership Council Chair)RichardKovacsMD, MACC(ACC Sports and Exercise Cardiology Leadership Council Founding Co-Chair, and Immediate Past President, American College of Cardiology)
doi : 10.1016/j.jacc.2021.02.002
Volume 77, Issue 10, 16 March 2021, Pages 1368-1371
Addressing Equity and More in 2021: Call From Fellows-in-Training & Early Career Section Editors
Jason J.HanMDaMuthiahVaduganathanMD, MPHbCelina M.YongMD, MBA, MScc
doi : 10.1016/j.jacc.2021.02.001
Volume 77, Issue 10, 16 March 2021, Pages 1372-1373
Lack of Guideline-Directed Medical Therapy in Patients Undergoing Endovascular Procedures for Critical Limb Ischemia
FiorellaLlanos-CheaMDQurat-Ul-AinJelaniMDCamilaTrejo-ParedesMDJeptha P.CurtisMDCraig S.ParzynskiMSJiamingHuangMSKamil F.FaridiMDJeffreyTurnerMDKim G.SmolderenPhDCarlosMena-HurtadoMD
doi : 10.1016/j.jacc.2020.12.063
Volume 77, Issue 10, 16 March 2021, Pages 1374-1375
SGLT2 Inhibitors: Who Should Prescribe Them for Patients With Heart Failure?
Richard K.ChengMD, MScDeidre M.MooneyMD, MPHChristopher V.ChienMDKevin S.ShahMDAmandaVestMBBS, MPHJohn L.JefferiesMD, MPH
doi : 10.1016/j.jacc.2021.01.020
Volume 77, Issue 10, 16 March 2021, Pages 1375-1377
Hypertrophic Cardiomyopathy as Congenital Heart Disease
TomoakiMurakamiMD, PhDMasahiroShiraishiMD
doi : 10.1016/j.jacc.2020.11.077
Volume 77, Issue 10, 16 March 2021, Pages 1377-1378
Reply: Hypertrophic Cardiomyopathy as Congenital Heart Disease
AlekseiZyrianovMDPaoloSpiritoMDPaoloFerrazziMDLauraPezzoliPhDMariaIasconePhD
doi : 10.1016/j.jacc.2020.12.045
Volume 77, Issue 10, 16 March 2021, Pages 1378-1379
